Arbios Systems files Chapter 11
This article was originally published in The Gray Sheet
Executive Summary
The maker of the Sepet liver assist device files for bankruptcy protection on Jan. 9, with plans to sell the company through a bid solicitation plan. In a phase I/II clinical trial, 11 out of 14 patients saw a reduction in hepatic encephalopathy. Last summer, Arbios acknowledged it would need to raise considerable capital to conduct the additional trials needed to launch the device in the U.S. and Europe (1"The Gray Sheet" June 9, 2008, p. 10). The company announced in August it had suspended all operations except fundraising efforts to support a Sepet launch or to enter into a strategic partnership
You may also be interested in...
Startups Persevere Toward Gaining Artificial Liver Approval
The potential market opportunity for an artificial liver keeps players in the game, even though many companies have tried and failed in the past
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.